VivoSeq
Other

Graft Vs Host Disease

3

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Graft Vs Host Disease is an early-stage landscape with 3 programs across 4 companies. The most active players are Incyte, Immunex, Tarix Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

30/100

Attrition Rate

47/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

1 program

PreclinicalI

Immunex

1 program

PreclinicalT

Tarix Pharmaceuticals

0 programs

PreclinicalA

AbGenomics B.V Taiwan Branch

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical3

Pacritinib

OrsoBio, Inc

Ruxolitinib

Incyte

Etanercept

Immunex

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSProtein / enzyme133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

15

clinical trials

Terminated6 · 40%
Completed3 · 20%
Active, not recruiting2 · 13%
Recruiting2 · 13%
Unknown status1 · 7%
Withdrawn1 · 7%

Clinical Trials

Trial Activity

15 trials

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT05531786·50 enrolled
Prospective Multicenter Randomized Study of Ruxolitinib Plus Etanercept vs Ruxolitinib Alone for Corticosteroid-Refractory Severe Acute GVHD After Allogeneic HSCT
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Preclinical·NCT07184853·122 enrolled
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT03842696·43 enrolled
Development and Psychometric Testing of a Pediatric Chronic Graft- Versus-Host Disease (GVHD) Symptom Scale (PCSS)
Active, not recruiting·National Cancer Institute (NCI)·N/A·NCT04044365·139 enrolled
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT01790568·26 enrolled
Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
Completed·UUniversity Health Network, Toronto·Phase 2·NCT00775632·78 enrolled
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Completed·—·Phase 3·NCT05663827·6 enrolled
Upfront Ruxolitinib for Chronic Graft-vs-host Disease
Terminated·—·Phase 1·NCT06695507·1 enrolled
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
Terminated·SSandeep Jain, MD·Phase 1/2·NCT02975557·15 enrolled
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00675441·5 enrolled
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
Terminated·XXenikos·Phase 3·NCT04934670·12 enrolled
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
Terminated·OOcugen·Phase 3·NCT03591874·59 enrolled
A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant
Terminated·AAbGenomics B.V Taiwan Branch·Phase 1·NCT02436460·4 enrolled
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation
Withdrawn·TTarix Pharmaceuticals·Phase 2·NCT01882374
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
Unknown status·—·Phase 2·NCT01158105·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)